> Neurapheresis™ Clinical and Impact
Clinically Demonstrated to Clear CSF and Improve outcomes
Neurapheresis radically reduces blood and protein compared to EVD and Lumbar Drain. 10-12 day acceleration in return to normal vs. standard of care. Reduces inflammation, shunt risk, and long-term injury
40 patient IDE-trials show Powerful CSF Clearance,
Validated across 5 Top US Centers
PILLAR XT study
N=27 aSAH patients
64.7%
reduction in cranial blood¹
85.8%
reduction in spinal blood²
82.4%
reduction of Total Protein to normal range²
Pharaoh Neuro
1. Internal comparison to Sponsored Retrospective Study at Memorial Hermann (not yet published)
2. Internal comparison to Koopman I, et al. Journal of the Neurological Sciences 2020;415:116899.
Demonstrated Efficacy Means Better Outcomes
72%
↓ Strokes
40%
↓ Shunts needed
64%
↓ Shunts needed
57/59%
↓ Edema / Seizures
Reducing Complications Avoids High-Cost Events, Driving Economic Value at Tier 1 Centers
$192,000
Median cost of patient with stroke in 90 days¹
40%
Median cost of patient receiving shunt in 90 days²
64%
Median cost per readmission³
57/59%
Median cost of a patient with edema or seizure event in 90 days¹
Pharaoh Neuro
1. 2021 Charalambous et al, A Nationwide Analysis of Aneurysmal Subarachnoid Hemorrhage Mortality, Complications and Health Economics in the United States 2. 2019 Adil et al, Healthcare Economics of Hydrocephalus After Aneurysmal Subarachnoid Hemorrhage in the United States 3. 2017 Dasenbrock et al, Readmission After Aneurysmal Subarachnoid Hemorrhage
1. In patients treated with the Neurapheresis™ system, when compared to standard of care (p=0.005) 2. Among patients with acute hydrocephalus, when compared to standard of care, (50.0% vs. 83.0%, p=0.0383) 3. For patients treated with the Neurapheresis™ system, when compared to publication on a similar population in Dasenbrock, 2017 (not significant sample size). 4. For patients treated with the Neurapheresis™ system, when compared to standard of care (not significant sample size). 5. While 10% of patients treated with standard of care were in LTAC, hospice or dead; no patients treated with the Neurapheresis™ system were in LTAC, hospice or dead at 30-days post-treatment.